loading page

“Techquity” in pediatric, adolescent and young adult oncology: addressing inequities through artificial intelligence and immersive technologies
  • Vidya Puthenpura,
  • Mary Hunter,
  • Asher Marks
Vidya Puthenpura
Yale University School of Medicine

Corresponding Author:vidya.puthenpura@yale.edu

Author Profile
Mary Hunter
Lucile Packard Children's Hospital School
Author Profile
Asher Marks
Yale University School of Medicine
Author Profile

Abstract

Health disparities in pediatric, adolescent, and young adult (AYA) oncology remain a significant challenge, with socioeconomic status, geographic location, race, and ethnicity contributing to unequal access to care and poorer outcomes. Emerging technologies, including artificial intelligence (AI) and immersive tools such as virtual and augmented reality (VR/AR), offer transformative solutions to address these inequities. AI has demonstrated potential in enhancing diagnostic accuracy, tailoring treatment plans, and providing personalized patient navigation to guide families through complex care pathways. Immersive technologies have shown promise in delivering equitable supportive care, including VR-based psychological support, pain management, physical rehabilitation, and patient education. This paper explores how integrating AI and immersive technology tools into cancer care can enhance quality of life, and bridge gaps in care delivery for pediatric and AYA patients. Additionally, the increasing availability of internet-enabled devices presents an unprecedented opportunity to overcome traditional barriers to care in underserved populations. The paper also addresses critical challenges, including the digital divide, ethical considerations, and cost barriers, while proposing strategies for equitable implementation. By leveraging these technologies, healthcare providers can create more inclusive and effective treatment environments, ensuring that the benefits of innovation reach all patients, regardless of background or circumstance.
26 Nov 2024Submission Checks Completed
26 Nov 2024Assigned to Editor
26 Nov 2024Submitted to Pediatric Blood & Cancer
27 Nov 2024Review(s) Completed, Editorial Evaluation Pending
27 Nov 2024Reviewer(s) Assigned
15 Dec 2024Editorial Decision: Revise Major